DelveInsight’s report titled “Neurofibromatosis Type 1 Pipeline Insight 2023” offers extensive information on more than 10+ companies and over 10+ pipeline drugs in the field of Neurofibromatosis Type 1 research. The Neurofibromatosis Type 1 pipeline report encompasses detailed profiles of the pipeline drugs for Neurofibromatosis Type 1, including information on Neurofibromatosis Type 1 clinical trial and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the Neurofibromatosis Type 1 emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Neurofibromatosis Type 1 pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Neurofibromatosis Type 1 clinical trial studies conducted for Neurofibromatosis Type 1, any NDA approvals obtained for Neurofibromatosis Type 1, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Neurofibromatosis Type 1 Pipeline treatment landscape of the report, click here @ Neurofibromatosis Type 1 Pipeline Outlook

 

Key Takeaways from the Neurofibromatosis Type 1 Pipeline Report

• DelveInsight’s Neurofibromatosis Type 1 Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Neurofibromatosis Type 1 Companies are working in the market include NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis, Array BioPharma, and others
• Promising Neurofibromatosis Type 1 Pipeline Therapies in the various stages of development include Selumetinib, Selumetinib capsule formulation, Mirdametinib (PD-0325901) oral capsule or dispersible tablet, HL-085, FCN-159, AL2846 capsules, and others.
• On May, 2023, Shanghai Kechow Pharma Inc announced drug named HL-085 in the market of phase 2. This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN).
• On April, 2023, AstraZeneca has announced drug named Selumetinib capsule formulation in the market of phase 1 and 2. This study is designed to define a dosing regimen and assess the pharmacokinetics (PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to < 7 years with NF1 related symptomatic, inoperable PN.

 

Neurofibromatosis Type 1 Overview

Neurofibromatosis type 1 is a condition characterized by changes in skin coloring (pigmentation) and the growth of tumors along nerves in the skin, brain, and other parts of the body. The signs and symptoms of this condition vary widely among affected people.

 

For further information, refer to the detailed Neurofibromatosis Type 1 Unmet Needs, Neurofibromatosis Type 1 Market Drivers, and Market Barriers, click here for Neurofibromatosis Type 1 Ongoing Clinical Trial Analysis

 

Neurofibromatosis Type 1 Emerging Drugs Profile

• Mirdametinib: SpringWorks Therapeutics
• NFX-179: NFlection Therapeutics

 

Neurofibromatosis Type 1 Pipeline Therapeutics Assessment

There are approx. 10+ Neurofibromatosis Type 1 companies which are developing the therapies for Neurofibromatosis Type 1. The Neurofibromatosis Type 1 companies which have their Neurofibromatosis Type 1 drug candidates in the most advanced stage, i.e. phase II include, SpringWorks Therapeutics.

 

Request a sample and discover the recent advances in Neurofibromatosis Type 1 Ongoing Clinical Trial Analysis and Medications, click here @ Neurofibromatosis Type 1 Treatment Landscape

 

Nephroblastoma Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Neurofibromatosis Type 1 Therapeutics Market include-

NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis, Array BioPharma, and others.

 

Dive deep into rich insights for drugs for Neurofibromatosis Type 1 Pipeline, click here @ Neurofibromatosis Type 1 Unmet Needs and Analyst Views

 

Scope of the Neurofibromatosis Type 1 Pipeline Report

• Coverage- Global
• Neurofibromatosis Type 1 Companies- NFlection Therapeutics, SpringWorks Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis, Array BioPharma, and others.
• Neurofibromatosis Type 1 Therapies- Selumetinib, Selumetinib capsule formulation, Mirdametinib (PD-0325901) oral capsule or dispersible tablet, HL-085, FCN-159, AL2846 capsules, and others.
• Neurofibromatosis Type 1 Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Neurofibromatosis Type 1 Merger and acquisitions, Neurofibromatosis Type 1 Licensing Activities @ Neurofibromatosis Type 1 Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Neurofibromatosis Type 1 Executive Summary
3. Neurofibromatosis Type 1: Overview
4. Neurofibromatosis Type 1 Pipeline Therapeutics
5. Neurofibromatosis Type 1 Therapeutic Assessment
6. Neurofibromatosis Type 1 – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Neurofibromatosis Type 1 Collaboration Deals
9. Late Stage Products (Phase III)
10. NPC-12: Nobelpharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Mirdametinib: SpringWorks Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Neurofibromatosis Type 1 Key Companies
19. Neurofibromatosis Type 1 Key Products
20. Neurofibromatosis Type 1- Unmet Needs
21. Neurofibromatosis Type 1- Market Drivers and Barriers
22. Neurofibromatosis Type 1- Future Perspectives and Conclusion
23. Neurofibromatosis Type 1 Analyst Views
24. Neurofibromatosis Type 1 Key Companies
25. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage